Thirty-day outcomes following transcarotid artery revascularization with integrated embolic protection: The PERFORMANCE III study.
J Vasc SurgMay 26, 2026 (epub)
Sean P Lyden, Robert R Mendes, Nicolas J Mouawad et al.
✦ AI-curated · Sources linked
In 30 seconds
The PERFORMANCE III study evaluated the safety and effectiveness of transcarotid artery revascularization with integrated embolic protection (TCAR-IEP) in high-risk patients. This multicenter, nonrandomized trial included 146 patients and reported a 30-day major adverse event rate of 0.7%, significantly below the performance goal of 11.0%. The study achieved a technical success rate of 99.3%.
Key findings
- The 30-day rate of major adverse events was 0.7% (1/145), with no strokes or neurological deaths.
- Technical success was achieved in 99.3% of patients.
- The mean flow reversal time was 7.4 ± 3.5 minutes.
- No cranial nerve injuries, stent thromboses, or blood transfusions were reported.
Why it matters
These findings suggest that TCAR-IEP may significantly enhance patient safety during carotid stenting procedures, particularly for those at high risk for complications. The low rate of adverse events supports its use in clinical practice.